Laparoscopic Duodenal–Jejunal Exclusion in the Treatment of Type 2 Diabetes Mellitus in Patients with BMI < 30 kg/m2 (LBMI)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The association between medical and dietetic–behavioral treatments of type 2 diabetes mellitus (T2DM) has demonstrated to have variable results. The surgical treatment of T2DM is justifiable after the observation of a successful glycemic control in patients submitted to Roux-en-Y gastric bypass and biliopancreatic diversion. Experiments have shown an important role of the proximal intestine in glycemia decrease and diabetes control.
Twenty diabetic patients underwent laparoscopic duodenal–jejunal exclusion. The variables studied were body mass index (BMI), fasting glycemia, glycosylated hemoglobin (HbA1c), and C-peptide, in the preoperative period and after 3 and 6 months.
There was a BMI decrease up to the third month and a weight stabilization between the third and sixth months. There was a significant reduction in fasting glycemia (43.8%) and HbA1c (22.8%) up to the sixth month (p < 0.001). C-peptide did not show any significant alteration until the third month, although there was a considerable increase (25%) between the third and the sixth months (p < 0.001). Only two patients were on oral medication after the sixth month.
Preliminary results have shown an important effect of the laparoscopic duodenal–jejunal exclusion in the treatment of T2DM. Studies with longer follow-up and a larger number of patients are necessary to better define the role of this new and promising procedure.
- Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–7. CrossRef
- Greenway SE, Greenway FL, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 2002;137:1109–17. CrossRef
- Eliasson B, Eeg-Olofsson K, Cederholm J, et al. Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes Metab. 2007;33:269–276. CrossRef
- Pories WJ, Macdonald KG, Flickinger EG, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992;215(6):633–42. CrossRef
- Pories WJ, Macdonald KG, Long SB, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222(3):339–52. CrossRef
- Lee WJ, Huang MT, Wang W, et al. Effects of obesity surgery on the metabolic syndrome. Arch Surg 2004;139:1088–92. CrossRef
- Madan AK, Orth W, Ternovits CA, et al. Metabolic syndrome: yet another comorbidity gastric bypass helps cure. Surg Obes Relat Dis 2006;2:48–51. CrossRef
- Mottin C, Padoin AV, Schroer C, et al. Behavior of type 2 diabetes mellitus in morbid obese patients submitted to gastric bypass. Obes Surg 2008;18(2):179–81. CrossRef
- Rubino F, Marescaux J. Effect of duodenal–jejunal exclusion in non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004;239:1–11. CrossRef
- Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006;244:741–9. CrossRef
- Neter J, Kutner MH, Nachtsheim CJ, et al. Applied linear statistical models. 4th ed. Chicago: Irwin; 1996.
- Cohen R, Schiavon C, Pinheiro J, et al. Duodenal–jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis 2007;3:195–7. CrossRef
- de Paula AL, Macedo A, Prudente L, et al. Laparoscopic sleeve gastrectomy with ileal interposition (“neuroendocrine brake”)—pilot study of a new operation. Surg Obes Relat Dis 2006;2:464–7. CrossRef
- Leifsson BG, Gislason HG. Laparoscopic Roux-en-Y gastric bypass with 2-metre long biliopancreatic limb for morbid obesity: technique and experience with the first 150 patients. Obes Surg 2005;15:35–42. CrossRef
- Näslund E, Backman L, Holst JJ, et al. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 1998;8(3):253–60. CrossRef
- Rodriguez-Grunert L, Galvão-Neto MP, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal–jejunal bypass sleeve. Surg Obes Relat Dis 2008;4(1):55–9. CrossRef
- Chobanian AV, Bakris GL, Black HR. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (JNC 7). JAMA 2003;289:2560–71. CrossRef
- Laparoscopic Duodenal–Jejunal Exclusion in the Treatment of Type 2 Diabetes Mellitus in Patients with BMI < 30 kg/m2 (LBMI)
Volume 19, Issue 3 , pp 307-312
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Diabetes mellitus
- Duodenal–jejunal exclusion
- Surgical technique
- Industry Sectors
- Author Affiliations
- 1. Gastrointestinal, Bariatric and Metabolic Surgery, Gastro Obeso Center, São Paulo, Brazil
- 2. Gastrointestinal, Bariatric and Metabolic Endoscopy, Gastro Obeso Center, São Paulo, Brazil
- 4. Rua Barata Ribeiro, 237-cj. 83/84, Cerqueira Cesar, São Paulo, SP, CEP: 01308-000, Brazil
- 3. Division of Bariatric and Metabolic Surgery, San Obeso Center, Guayaquil, GU, Ecuador